Cargando…

Antenatal and postnatal combined therapy for autoantibody-related congenital atrioventricular block

BACKGROUND: Autoantibody-related congenital heart block (CHB) is an autoimmune condition in which trans placental passage of maternal autoantibodies cause damage to the developing heart conduction system of the foetus. CASE PRESENTATION: We report a case of an Italian 31–year-old woman, in a good cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Mauro, Antonio, Caroli Casavola, Vita, Favia Guarnieri, Giovanna, Calderoni, Grazia, Cicinelli, Ettore, Laforgia, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219454/
https://www.ncbi.nlm.nih.gov/pubmed/24286473
http://dx.doi.org/10.1186/1471-2393-13-220
_version_ 1782342586296434688
author Di Mauro, Antonio
Caroli Casavola, Vita
Favia Guarnieri, Giovanna
Calderoni, Grazia
Cicinelli, Ettore
Laforgia, Nicola
author_facet Di Mauro, Antonio
Caroli Casavola, Vita
Favia Guarnieri, Giovanna
Calderoni, Grazia
Cicinelli, Ettore
Laforgia, Nicola
author_sort Di Mauro, Antonio
collection PubMed
description BACKGROUND: Autoantibody-related congenital heart block (CHB) is an autoimmune condition in which trans placental passage of maternal autoantibodies cause damage to the developing heart conduction system of the foetus. CASE PRESENTATION: We report a case of an Italian 31–year-old woman, in a good clinical status, referred to our Centre at 26 weeks of her first pregnancy, because of foetal bradycardia, found during routine foetal ultrasonography. Foetal echocardiography revealed a 3rd degree CHB, without any anatomical defects. Despite the mother was asymptomatic for autoimmune disease, anti-Ro/La were searched for, because of the hypothesis of autoantibody-related CHB. High title of maternal anti-Ro/SSA antibodies was found and diagnosis of an autoantibody-related CHB was made. A combination treatment protocol of the mother was started with oral betamethasone, plasmapheresis and IVIG. An emergency C-section was performed at 32 + 3 weeks of gestation because of a non-reassuring cardiotocography pattern. A male newborn (BW 1515 g, NGA, Apgar 8–10) was treated since birth with high-flow O2 for mild RDS. IVIG administration was started at one week, and then every two weeks, until complete disappearance of maternal antibodies from blood. Because of persistent low ventricular rate (<60/min), seven days following birth, pacemaker implantation was performed. The baby is now at 40th week with no signs of cardiac failure and free of any medications. CONCLUSION: Up to date, no guidelines have been published for the treatment of “in utero-CHB” and only anecdotal reports are available. It has been stated that a combination therapy protocol is effective in reversing a 2nd degree CHB, but not for 3rd degree CHB. In cases of foetal bradycardia, weekly foetal echocardiographic monitoring needs to be performed and in cases of 2nd degree CHB and 3rd degree CHB maternal therapy could be suggested, as in our case, to avoid foetal heart failure. In cases of 3rd degree CHB often pacemaker implantation is needed.
format Online
Article
Text
id pubmed-4219454
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42194542014-11-05 Antenatal and postnatal combined therapy for autoantibody-related congenital atrioventricular block Di Mauro, Antonio Caroli Casavola, Vita Favia Guarnieri, Giovanna Calderoni, Grazia Cicinelli, Ettore Laforgia, Nicola BMC Pregnancy Childbirth Case Report BACKGROUND: Autoantibody-related congenital heart block (CHB) is an autoimmune condition in which trans placental passage of maternal autoantibodies cause damage to the developing heart conduction system of the foetus. CASE PRESENTATION: We report a case of an Italian 31–year-old woman, in a good clinical status, referred to our Centre at 26 weeks of her first pregnancy, because of foetal bradycardia, found during routine foetal ultrasonography. Foetal echocardiography revealed a 3rd degree CHB, without any anatomical defects. Despite the mother was asymptomatic for autoimmune disease, anti-Ro/La were searched for, because of the hypothesis of autoantibody-related CHB. High title of maternal anti-Ro/SSA antibodies was found and diagnosis of an autoantibody-related CHB was made. A combination treatment protocol of the mother was started with oral betamethasone, plasmapheresis and IVIG. An emergency C-section was performed at 32 + 3 weeks of gestation because of a non-reassuring cardiotocography pattern. A male newborn (BW 1515 g, NGA, Apgar 8–10) was treated since birth with high-flow O2 for mild RDS. IVIG administration was started at one week, and then every two weeks, until complete disappearance of maternal antibodies from blood. Because of persistent low ventricular rate (<60/min), seven days following birth, pacemaker implantation was performed. The baby is now at 40th week with no signs of cardiac failure and free of any medications. CONCLUSION: Up to date, no guidelines have been published for the treatment of “in utero-CHB” and only anecdotal reports are available. It has been stated that a combination therapy protocol is effective in reversing a 2nd degree CHB, but not for 3rd degree CHB. In cases of foetal bradycardia, weekly foetal echocardiographic monitoring needs to be performed and in cases of 2nd degree CHB and 3rd degree CHB maternal therapy could be suggested, as in our case, to avoid foetal heart failure. In cases of 3rd degree CHB often pacemaker implantation is needed. BioMed Central 2013-11-29 /pmc/articles/PMC4219454/ /pubmed/24286473 http://dx.doi.org/10.1186/1471-2393-13-220 Text en Copyright © 2013 Di Mauro et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Di Mauro, Antonio
Caroli Casavola, Vita
Favia Guarnieri, Giovanna
Calderoni, Grazia
Cicinelli, Ettore
Laforgia, Nicola
Antenatal and postnatal combined therapy for autoantibody-related congenital atrioventricular block
title Antenatal and postnatal combined therapy for autoantibody-related congenital atrioventricular block
title_full Antenatal and postnatal combined therapy for autoantibody-related congenital atrioventricular block
title_fullStr Antenatal and postnatal combined therapy for autoantibody-related congenital atrioventricular block
title_full_unstemmed Antenatal and postnatal combined therapy for autoantibody-related congenital atrioventricular block
title_short Antenatal and postnatal combined therapy for autoantibody-related congenital atrioventricular block
title_sort antenatal and postnatal combined therapy for autoantibody-related congenital atrioventricular block
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4219454/
https://www.ncbi.nlm.nih.gov/pubmed/24286473
http://dx.doi.org/10.1186/1471-2393-13-220
work_keys_str_mv AT dimauroantonio antenatalandpostnatalcombinedtherapyforautoantibodyrelatedcongenitalatrioventricularblock
AT carolicasavolavita antenatalandpostnatalcombinedtherapyforautoantibodyrelatedcongenitalatrioventricularblock
AT faviaguarnierigiovanna antenatalandpostnatalcombinedtherapyforautoantibodyrelatedcongenitalatrioventricularblock
AT calderonigrazia antenatalandpostnatalcombinedtherapyforautoantibodyrelatedcongenitalatrioventricularblock
AT cicinelliettore antenatalandpostnatalcombinedtherapyforautoantibodyrelatedcongenitalatrioventricularblock
AT laforgianicola antenatalandpostnatalcombinedtherapyforautoantibodyrelatedcongenitalatrioventricularblock